Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases, is to be sold to Genfit. With this acquisition, Genfit intends to expand its product portfolio
Tags :Matthias Staehelin
VISCHER has advised Forty51 Ventures, a Biotech venture capital firm, on its first fund, Forty51 Ventures Fund I which has raised USD 43 million in a first closing and is domiciled in Luxemburg. VISCHER has supported,
Mosanna Therapeutics, a Basel-based biotechnology company, has closed a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of the molecule MOS118 and for regulatory activities in
Novaremed, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for non-opioid investigational drug, NRD.E1. The
Eurocine Vaccines and Redbiotec have signed a research and collaboration agreement for the development of vaccine candidates against herpes simplex virus type 2. Under the terms of the agreement, Eurocine will have exclusive international rights to
Engimmune Therapeutics, a Swiss biotech company based in Basel developing novel T-cell receptor (TCR)-based therapeutics, has closed a CHF 15.5m seed financing round. The round was led by the investors Pureos Bio-ventures and Novo
Alloy Therapeutics, a Boston based biotechnology ecosystem company, has entered into a definitive agreement to acquire deepCDR Biologics, a privately held Basel based developer of deep learning technology for antibody discovery and optimisation. Alloy will
Vifor Pharma acquires the Swiss firm Inositec, a clinical stage biopharmaceutical company which is developing first-in-class treatments for unmet medical need. Through this acquisitions, Vifor Pharma will be spearheading the vascular calcification field to improve
GlycoEra has successfully completed a CHF 45 million Series A financing round, co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics, from which GlycoEra was spun-out, also participated in this round. GlycoEra’s
MiniNaviDent has received an investment by Straumann Holding to further develop and market its Denacam system, a miniaturized dynamic navigation system for dental implants. With the investment, Straumann obtained a 39% stake of mininavident. The two
